These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7525800)

  • 1. [Present status of developing hepatitis C vaccines].
    Arakawa Y; Moriyama M; Shikata T
    Nihon Naika Gakkai Zasshi; 1994 Feb; 83(2):245-51. PubMed ID: 7525800
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current status and strategy of the research on hepatitis C vaccine].
    Nie Q; Li M
    Zhonghua Liu Xing Bing Xue Za Zhi; 1998 Feb; 19(1):47-9. PubMed ID: 10322709
    [No Abstract]   [Full Text] [Related]  

  • 3. Nucleic acid vaccines against hepatitis viruses.
    Howard CR; Gray L; D'Mello F; Christopher J; Craske J
    Dev Biol Stand; 1998; 92():157-62. PubMed ID: 9554270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccination against hepatitis C.
    Dueñas-Carrera S
    Curr Opin Mol Ther; 2004 Apr; 6(2):146-50. PubMed ID: 15195926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.
    Houghton M
    Immunol Rev; 2011 Jan; 239(1):99-108. PubMed ID: 21198667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene vaccination for hepatitis C.
    Inchauspé G
    Springer Semin Immunopathol; 1997; 19(2):211-21. PubMed ID: 9406347
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune responses against hepatitis C virus structural proteins following genetic immunisation.
    Inchauspé G; Major ME; Nakano I; Vivitski L; Maisonnas M; Trépo C
    Dev Biol Stand; 1998; 92():163-8. PubMed ID: 9554271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.
    Yusim K; Fischer W; Yoon H; Thurmond J; Fenimore PW; Lauer G; Korber B; Kuiken C
    J Gen Virol; 2010 May; 91(Pt 5):1194-206. PubMed ID: 20053820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Forecasting of hepatitis C virus CTL epitopes and design of multi-epitopes vaccine].
    Li D; Xie YW; Xue XP; Bai XF; Jia ZS
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):786-7. PubMed ID: 19874698
    [No Abstract]   [Full Text] [Related]  

  • 11. Strategies and prospects for vaccination against the hepatitis C viruses.
    Houghton M
    Curr Top Microbiol Immunol; 2000; 242():327-39. PubMed ID: 10592667
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations.
    Gordon EJ; Bhat R; Liu Q; Wang YF; Tackney C; Prince AM
    J Infect Dis; 2000 Jan; 181(1):42-50. PubMed ID: 10608749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominance of antibodies to hepatitis C virus envelope proteins in various disease statuses of hepatitis C.
    PodurI CD; Khanna A; Khundmiri SJ; Khaja MN; Kumar KS; Sugunan VS; Habibullah CM; Das MR
    Acta Virol; 2001 Feb; 45(1):1-6. PubMed ID: 11394572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
    Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
    Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatitis C vaccine. Current status].
    Forns X
    Gastroenterol Hepatol; 1996; 19(6):317-9. PubMed ID: 8754421
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins.
    Sarobe P; Lasarte JJ; García N; Civeira MP; Borrás-Cuesta F; Prieto J
    J Viral Hepat; 2006 Jan; 13(1):47-55. PubMed ID: 16364082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
    Siler CA; McGettigan JP; Dietzschold B; Herrine SK; Dubuisson J; Pomerantz RJ; Schnell MJ
    Virology; 2002 Jan; 292(1):24-34. PubMed ID: 11878905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatitis C virus: troublesome vaccination and treatment].
    Carreño V
    Rev Clin Esp; 1993 Mar; 192(4):155-6. PubMed ID: 8386842
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis C vaccine approaches phase II trial.
    McNeil C
    J Natl Cancer Inst; 2006 Mar; 98(5):301-2. PubMed ID: 16507825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.